SCHEMBL573096

SCHEMBL573096

O=[N+]([O-])c1cc(F)c(OCCN2CCOCC2)cc1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MAPT P10636 4/20 0.50
NPSR1 Q6W5P4 2/20 0.50
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.45
CHEK1 O14757 1/20 0.45
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213401 0.81 CYP1A2 (0.65) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL2717838 0.81 CYP1A2 (0.52) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL212946 0.81 CYP1A2 (0.65) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL572541 0.81 KDM4E (0.67) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL30402766 0.81 KDM4E (0.67) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL25378553 0.79 CYP1A2 (0.68) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL17609969 0.79 CYP1A2 (0.57) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL1926359 0.78 CYP1A2 (0.60) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL1852361 0.78 CYP2D6 (0.88) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL6034052 0.78 POLB (0.52) ALDH1A1KDM4EMAPTPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160046625-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC (US) 2016-02-18 US disclosed
US-9115127-B2 Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase AMGEN INC. (US) 2015-08-25 US disclosed
US-20130217668-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2013-08-22 US disclosed
EP-2611784-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE Amgen, Inc (US) 2013-07-10 EP disclosed
WO-2012018668-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046625-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE BCL6, DCK, FLI1 CYP1A2 1226/4885CYP2D6 1864/4885CYP2C19 1234/4885
US-20130217668-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE BCL6, DCK, FLI1 CYP1A2 1226/4885CYP2D6 1864/4885CYP2C19 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.